一种新的二肽H-MGL部分改善stz诱导的老年痴呆雄性大鼠的记忆损伤。

Sarieh Ghasempour, Nader Maghsoudi, Homa Manaheji, Rasoul Ghasemi, Ali Jaafarisuha, Jalal Zaringhalam
{"title":"一种新的二肽H-MGL部分改善stz诱导的老年痴呆雄性大鼠的记忆损伤。","authors":"Sarieh Ghasempour, Nader Maghsoudi, Homa Manaheji, Rasoul Ghasemi, Ali Jaafarisuha, Jalal Zaringhalam","doi":"10.32598/bcn.2023.401.3","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Alzheimer disease (AD) is a progressive neurodegenerative disorder that is identified by the gradual decline in memory and cognitive function. It is classified by the deposition of Aβ plaques, the build-up of intracellular neurofibrillary tangle (NFT), and neuron loss. Neurotrophic factors play a critical role in the treatment of AD. However, utilizing such neurotrophins has encountered certain difficulties and side effects. Novel technological advancements prioritize innovative dipeptide usage, which offers fewer side effects.</p><p><strong>Methods: </strong>The present study endeavors to analyze the compound hexamethylenediamide bis-(N-monosuccinyl-glutamyl-lysine) (lab name: H-MGL), a newly discovered neurotrophin mimetic dipeptide, to alleviate memory impairment in an intracerebroventricular single dose streptozotocin (STZ)-induced Alzheimer model in rats. We arranged 4 groups: Sham and groups receiving STZ and STZ + H-MGL (1 and 2 mg/kg). The H-MGL was administered consecutively for 14 days following the STZ injection. Then, the Morris water maze test was performed.</p><p><strong>Results: </strong>The findings suggest that administration of STZ caused a significantly increment in mean escape latency and mean traveled distance in acquisition days. H-MGL at a 1 mg/kg dosage failed to yield any notable improvement in rats compared to STZ. By contrast, 2 mg/kg of H-MGL dosage led to a significant decrease in the latency to first platform crossing and frequency of platform crossings.</p><p><strong>Conclusion: </strong>Consequently, the findings above have engendered the notion that H-MGL partially ameliorates cognitive impairment, so it may hold promise for having low side effects to alleviate cognitive deficits in AD or potentially decrease the symptoms associated with its progression.</p>","PeriodicalId":8728,"journal":{"name":"Basic and Clinical Neuroscience Journal","volume":"76 1","pages":"583-594"},"PeriodicalIF":0.0000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12198738/pdf/","citationCount":"0","resultStr":"{\"title\":\"A New Dipeptide H-MGL Partially Ameliorating Memory Impairment in an STZ-induced Alzheimer Model in Male Rats.\",\"authors\":\"Sarieh Ghasempour, Nader Maghsoudi, Homa Manaheji, Rasoul Ghasemi, Ali Jaafarisuha, Jalal Zaringhalam\",\"doi\":\"10.32598/bcn.2023.401.3\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Alzheimer disease (AD) is a progressive neurodegenerative disorder that is identified by the gradual decline in memory and cognitive function. It is classified by the deposition of Aβ plaques, the build-up of intracellular neurofibrillary tangle (NFT), and neuron loss. Neurotrophic factors play a critical role in the treatment of AD. However, utilizing such neurotrophins has encountered certain difficulties and side effects. Novel technological advancements prioritize innovative dipeptide usage, which offers fewer side effects.</p><p><strong>Methods: </strong>The present study endeavors to analyze the compound hexamethylenediamide bis-(N-monosuccinyl-glutamyl-lysine) (lab name: H-MGL), a newly discovered neurotrophin mimetic dipeptide, to alleviate memory impairment in an intracerebroventricular single dose streptozotocin (STZ)-induced Alzheimer model in rats. We arranged 4 groups: Sham and groups receiving STZ and STZ + H-MGL (1 and 2 mg/kg). The H-MGL was administered consecutively for 14 days following the STZ injection. Then, the Morris water maze test was performed.</p><p><strong>Results: </strong>The findings suggest that administration of STZ caused a significantly increment in mean escape latency and mean traveled distance in acquisition days. H-MGL at a 1 mg/kg dosage failed to yield any notable improvement in rats compared to STZ. By contrast, 2 mg/kg of H-MGL dosage led to a significant decrease in the latency to first platform crossing and frequency of platform crossings.</p><p><strong>Conclusion: </strong>Consequently, the findings above have engendered the notion that H-MGL partially ameliorates cognitive impairment, so it may hold promise for having low side effects to alleviate cognitive deficits in AD or potentially decrease the symptoms associated with its progression.</p>\",\"PeriodicalId\":8728,\"journal\":{\"name\":\"Basic and Clinical Neuroscience Journal\",\"volume\":\"76 1\",\"pages\":\"583-594\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12198738/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Basic and Clinical Neuroscience Journal\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.32598/bcn.2023.401.3\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Basic and Clinical Neuroscience Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.32598/bcn.2023.401.3","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

阿尔茨海默病(AD)是一种进行性神经退行性疾病,以记忆和认知功能逐渐下降为特征。它可分为β斑块的沉积、细胞内神经原纤维缠结(NFT)的形成和神经元的丧失。神经营养因子在阿尔茨海默病的治疗中起着关键作用。然而,利用这些神经营养素遇到了一定的困难和副作用。新的技术进步优先考虑创新的二肽使用,它提供更少的副作用。方法:研究新发现的拟神经营养物质二肽化合物六亚二胺双-(n -单琥珀酰-谷氨酰赖氨酸)(实验室名称:H-MGL)对单剂量链脲佐剂(STZ)诱导的老年痴呆模型大鼠记忆损伤的缓解作用。将STZ组和STZ + H-MGL组(1、2 mg/kg)分为假手术组和对照组。H-MGL在STZ注射后连续给药14 d。然后进行Morris水迷宫实验。结果:STZ对小鼠的平均逃避潜伏期和平均行走距离均有显著影响。与STZ相比,1 mg/kg剂量的H-MGL对大鼠没有显著改善。2 mg/kg H-MGL剂量可显著降低小鼠第一次穿越平台的潜伏期和穿越平台的频率。结论:因此,上述研究结果产生了H-MGL部分改善认知障碍的概念,因此它可能有希望以低副作用减轻AD患者的认知缺陷或潜在地减少与AD进展相关的症状。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
A New Dipeptide H-MGL Partially Ameliorating Memory Impairment in an STZ-induced Alzheimer Model in Male Rats.

Introduction: Alzheimer disease (AD) is a progressive neurodegenerative disorder that is identified by the gradual decline in memory and cognitive function. It is classified by the deposition of Aβ plaques, the build-up of intracellular neurofibrillary tangle (NFT), and neuron loss. Neurotrophic factors play a critical role in the treatment of AD. However, utilizing such neurotrophins has encountered certain difficulties and side effects. Novel technological advancements prioritize innovative dipeptide usage, which offers fewer side effects.

Methods: The present study endeavors to analyze the compound hexamethylenediamide bis-(N-monosuccinyl-glutamyl-lysine) (lab name: H-MGL), a newly discovered neurotrophin mimetic dipeptide, to alleviate memory impairment in an intracerebroventricular single dose streptozotocin (STZ)-induced Alzheimer model in rats. We arranged 4 groups: Sham and groups receiving STZ and STZ + H-MGL (1 and 2 mg/kg). The H-MGL was administered consecutively for 14 days following the STZ injection. Then, the Morris water maze test was performed.

Results: The findings suggest that administration of STZ caused a significantly increment in mean escape latency and mean traveled distance in acquisition days. H-MGL at a 1 mg/kg dosage failed to yield any notable improvement in rats compared to STZ. By contrast, 2 mg/kg of H-MGL dosage led to a significant decrease in the latency to first platform crossing and frequency of platform crossings.

Conclusion: Consequently, the findings above have engendered the notion that H-MGL partially ameliorates cognitive impairment, so it may hold promise for having low side effects to alleviate cognitive deficits in AD or potentially decrease the symptoms associated with its progression.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信